

AUG 06 2003

*CCH CENTER 1600/2900

Sefra No. 09/459,808

Patent Docket No. P0978-1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of

Group Art Unit: 1647

Ashkenazi

Examiner: D. Romeo

Serial No.: 09/459,808

Filed: December 13, 1999

For:

Apo-2 Ligand

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Your petitioner, Genentech, Inc., having a place of business at 1 DNA Way, South San Francisco, California 94080-4990 in the county of San Mateo has reviewed the evidentiary documents set forth hereinbelow and certifies to the best of Genentech's knowledge and belief that title in and to the herein application and in the referenced U.S. Patent No.6,030,945 reside in Genentech, Inc.

Your petitioner, Genentech, Inc., represents that it is the owner of the entire right, title, and interest in and to application U.S. Serial No.09/459,808., filed December 13, 1999, by virtue of an assignment recorded on March 11, 1996 at Reel 8012, Frame 0630, and is also the owner of the entire right, title and interest in and to U.S. Patent No.6,030,945 filed January 9, 1996 and issued February 29, 2000, by virtue of an assignment recorded on March 11, 1996 at Reel 8012, Frame 0630.

Your petitioner hereby disclaims the terminal part of any patent granted on the herein application Serial No. 09/459,808 that would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of said Patent No. 6,030,945, and hereby agrees that any patent so granted on the herein application Serial No. 09/459,808 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title

Serial No. 09/459,808

to U.S. Patent No. 6,030,945, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of Patent No. 6,030,945 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above. Petitioner reserves the right to extend the shortened term of any patent granted on the above-identified application due to regulatory delays pursuant to 35 U.S.C. §156.

I am an attorney of record and empowered to act on behalf of Genentech, Inc. as an attorney of the company.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

The Commissioner is authorized to charge the statutory fee of \$110 required for filing this Disclaimer to Deposit Account No. 07-0630. Please charge any deficiency or credit any overpayment to Account 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: August 1, 2003

Maischanf Diane L. Marschang Reg. No. 35,600

Telephone No. (650) 225-5416